Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2018.0271
News & Views
|
Developing personalized novel therapies for pancreatic cancer.
|
Anastasios Machairas, MD, PhD.
|
Affiliation: Anastasios Machairas, (AM), 3rd Department of Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
E-mail: anmach@med.uoa.gr
|
Abstract
Despite standardization of surgery in resectable pancreatic cancer and adjuvant chemotherapy, recurrence and death rates remain high. The recent evidence of extensive genetic heterogeneity makes essential the development of targeted drugs and their individualized response to achieve effective personalized treatment.
This article summarizes recent advances in the discovery of novel therapeutic targets and robust predictive biomarkers applying NGS technologies in patient-derived samples.
(Citation: Gastric & Breast Cancer 2018; 13(1): 15-20)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
